Question-and-Answer Session
Operator
(Operator's instruction) Your first question comes from the line of Bill Boutin - Indusino Capital Management.
Bill Boutin - Indusino Capital Management
Real quick, could you guys go over again your plan, just on the Company, until the end of the year?
Dr. Christopher Anzalone
Sure, we believe we have sufficient capital on the books and opportunities that we can get to the end of the year and into 2010. We are pursuing a number of avenues. I mentioned 10 of them. These are the most pressing. However, we are really walking down multiple pads beyond this 10, I will repeat this however.
One is a single or series of partnerships for Calando. We believe that that could bring in capital to Calando and possibly to Arrowhead, direct investments into Calando from strategic and/or financial investors. Again, Calando and Unidym are our two greatest consumers of capital but to the extent that we can source direct investments into those. It will greatly enhance our balance sheet. Number three is funded JDAs and partnerships for Unidym. Number four is revenue generator from the Unidym sales. Number five is license fees to Unidym. Number six is the sale of Unidym's book materials business. Number seven is direct investments into Unidym from strategic and/or financial investors. Again as I mentioned earlier in the call, we are actually pursuing that as we speak. Number eight is the sale of Tego. Nine is Tego license fees and ten is continued schedule payouts from the 2008 sale of Ionics.
Operator
Your next question comes from the line of Jeff Ram - Stifel, Nicolaus & Company.
Jeff Ram - Stifel, Nicolaus & Company
Could you talk a little bit about the, you touched on the cartilage breakthrough and Nanotope, what that could mean and is there a potential to partner up with something like that to raise cash?
Dr. Christopher Anzalone
Yes. So Nanotope has at least two primary areas right now. Of course the spinal cord regeneration candidates that we have been working out for quite some time and we are continuing to optimize that formulation and as you point out this new candidate for cartilage regeneration. What we have seen there is we believe truly stunning. What we have seen in our model is the ability to regenerate a lost cartilage and it appears that that new cartilage is virtually indistinguishable from native non-injured cartilage. We are excited about this, to say the least, and we are actively talking to other companies about partnering that. We believe we can partner that fairly early, far before the clinic we think that will help us to defray the cost of the clinical trials.
- To read the full transcript on Seeking Alpha, click here »
